The corresponding PCa risks for BRCA2 carriers were 27% (95% CI 17–41%) and 60% (95% CI 43–78%), respectively (Table 2; Fig. 1A and 1B). This evidence concerns the gene BRCA2 and posterior cortical atrophy.